Researchers from the Republic of Korea say that rescue therapy with tenofovir disoproxil fumarate (TDF) alone is an appropriate option for patients with multidrug resistant chronic hepatitis B virus (HBV) infection.
Although current guidelines recommend combination nucleos(t)ide analogue treatment for multidrug resistant patients, the team believes it is important to evaluate TDF monotherapy in this setting as long-term use of multiple drugs has cost and safety implications.
Of 446 patients included in this medical review, 156 were resistant to two prior antiviral therapies and thus considered multidrug resistant, while 290 displayed resistance to lamivudine alone.
Labels: HBV resistance, Korea, tenofovir